Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 5/20 | 0.40 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.40 |
| ▸ | STK17B | O94768 | 1/20 | 0.38 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL941398 | 0.82 | MMP1 (0.54) | MMP1FPR2PROKR1GPR119CNR1 | |
| SCHEMBL940675 | 0.80 | MMP13 (0.44) | MMP1FPR2PROKR1CNR1IP6K1 | |
| SCHEMBL943749 | 0.80 | MMP1 (0.56) | MMP1FPR2PROKR1GPR119LIPE | |
| SCHEMBL941379 | 0.79 | MMP1 (0.49) | MMP1FPR2PROKR1GPR119LIPE | |
| SCHEMBL942174 | 0.79 | GPR119 (0.54) | MMP1FPR2PROKR1GPR119LIPE | |
| SCHEMBL940600 | 0.78 | MMP1 (0.57) | MMP1FPR2PROKR1GPR119LIPE | |
| SCHEMBL941419 | 0.78 | MMP1 (0.49) | MMP1FPR2PROKR1GPR119LIPE | |
| SCHEMBL942627 | 0.78 | FPR2 (0.47) | MMP1FPR2PROKR1 | |
| SCHEMBL942540 | 0.78 | MMP1 (0.58) | MMP1FPR2PROKR1GPR119CNR1 | |
| SCHEMBL941286 | 0.77 | MMP1 (0.49) | MMP1FPR2PROKR1GPR119LIPE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2011-01-06 | — | — | US | disclosed |
| US-7754750-B2 | a -5 substituted 1-H,3-H-imidazolidine-2,4-dione such as 5-(2-{[4-(4'-fluoro[1,1'-biphenyl]-4-yl)-1-piperazinyl]sulfonyl}ethyl)-2,4-imidazolidinedione; protease inhibitors, especially metalloelastase (MMP12) | ASTRAZENECA AB (SE) | 2010-07-13 | — | — | US | disclosed |
| US-7625934-B2 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-12-01 | — | — | US | disclosed |
| US-20080306065-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-12-11 | — | — | US | disclosed |
| US-7427631-B2 | especially as inhibitors of MMP12 | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| US-20080171882-A1 | Metalloproteinase Inhibitors | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| EP-1370556-B1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-07-19 | — | — | EP | disclosed |
| EP-1676846-A2 | Hydantoin derivatives as MMP inhibitors | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| US-20040147573-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | US | disclosed |
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
| EP-1370536-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| EP-1370556-A1 | METALLOPROTEINASE INHIBITORS | AstraZeneca AB (SE) | 2003-12-17 | — | — | EP | disclosed |
| WO-2002074767-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002074750-A1 | METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003853-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP1 10/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20080306065-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP1 10/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20080171882-A1 | Metalloproteinase Inhibitors | MMP9, MMP12, MMP14 | MMP1 10/4885FPR2 737/4885PROKR1 2373/4885 |
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | MMP1 17/4885FPR2 1510/4885PROKR1 2106/4885 |
| US-20040147573-A1 | Metalloproteinase inhibitors | MMP12, MMP7, MMP10 | MMP1 14/4885FPR2 1887/4885PROKR1 2512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.